業績紹介

2018年 論文

  • Retrocaval Ureter Manifested after Ureteral Reimplantation for Ipsilateral Vesicoureteral Reflux: A Case Report.
    Katsui M, Asanuma H, Fukumoto K, Mizuno R, Oya M.
    Urol J. 2018 Apr 22;0(0).
  • Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy.
    Takamatsu K, Mizuno R, Omura M, Morita S, Matsumoto K, Shinoda K, Kosaka T, Takeda T, Shinojima T, Kikuchi E, Asanuma H, Oyama M, Mikami S, Oya M.
    Clin Genitourin Cancer. 2018 Mar 27. pii: S1558-7673(18)30232-5. doi: 10.1016/j.clgc.2018.03.012. [Epub ahead of print]
  • Change of the 5α/5β ratio of urinary steroid metabolites in benign prostatic hyperplasia patients treated with dutasteride.
    Maeda T, Kikuchi E, Hasegawa M, Homma K, Yasumizu Y, Hattori S, Kosaka T, Shinoda K, Miyajima A, Oya M.
    Clin Biochem. 2018 Mar 31. pii: S0009-9120(17)31100-1. doi: 10.1016/j.clinbiochem.2018.03.021. [Epub ahead of print]
  • Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer.
    Nishimura S, Ohashi T, Momma T, Sakayori M, Eriguchi T, Tanaka T, Yamashita S, Kosaka T, Oya M, Shigematsu N.
    Cancer Med. 2018 Mar 25. doi: 10.1002/cam4.1443. [Epub ahead of print]
  • Guidelines for treatment of renal injury during cancer chemotherapy 2016.
    Horie S, Oya M, Nangaku M, Yasuda Y, Komatsu Y, Yanagita M, Kitagawa Y, Kuwano H, Nishiyama H, Ishioka C, Takaishi H, Shimodaira H, Mogi A, Ando Y, Matsumoto K, Kadowaki D, Muto S.
    Clin Exp Nephrol. 2018 Feb;22(1):210-244.
  • Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
    Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI.
    Lancet Oncol. 2018 Apr;19(4):451-460.
  • Does switching the bacillus Calmette-Guerin strain affect clinical outcome in patients with recurrent non-muscle-invasive bladder cancer after initial bacillus Calmette-Guerin therapy?
    Niwa N, Kikuchi E, Matsumoto K, Kosaka T, Mizuno R, Oya M.
    Urol Oncol. 2018 Mar 9. pii: S1078-1439(18)30045-0. doi: 10.1016/j.urolonc.2018.02.005. [Epub ahead of print]
  • Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel.
    Kosaka T, Shinojima T, Morita S, Oya M.
    Cancer Sci. 2018 Mar 1. doi: 10.1111/cas.13556. [Epub ahead of print]
  • Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer.
    Hagiwara M, Kikuchi E, Tanaka N, Kosaka T, Mikami S, Saya H, Oya M.
    BMC Cancer. 2018 Jan 31;18(1):113. doi: 10.1186/s12885-018-3988-3.
  • Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Guerin therapy.
    Niwa N, Kikuchi E, Matsumoto K, Kosaka T, Mizuno R, Oya M.
    Urol Oncol. 2018 Feb;36(2):77.e15-77.e21.
  • Influence of dutasteride treatment on serum hormone levels and aging male symptoms in patients with benign prostatic enlargement.
    Maeda T, Kikuchi E, Hasegawa M, Homma K, Ando T, Suzuki K, Kaneko G, Mizuno R, Miyajima A, Oya M.
    Int J Urol. 2018 Jan;25(1):70-74.
  • Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmette-Guérin Therapy.
    Fukumoto K, Kikuchi E, Mikami S, Hayakawa N, Matsumoto K, Niwa N, Oya M.
    Ann Surg Oncol. 2018 Aug;25(8):2484-2491. doi: 10.1245/s10434-018-6498-2. Epub 2018 May 1.
  • Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer. Hongo H, Kosaka T, Oya M.
    Cancer Sci. 2018 Jul 10. doi: 10.1111/cas.13729. [Epub ahead of print]
  • Establishment of the optimal follow-up schedule after radical prostatectomy.
    Matsumoto K, Niwa N, Hattori S, Takeda T, Morita S, Kosaka T, Mizuno R, Shinojima T, Kikuchi E, Asanuma H, Oya M.
    Urol Oncol. 2018 Jul;36(7):341.e9-341.e14. doi: 10.1016/j.urolonc.2018.04.003. Epub 2018 May 3.
  • PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer.
    Yasumizu Y, Hongo H, Kosaka T, Mikami S, Nishimoto K, Kikuchi E, Oya M. Oncotarget. 2018 Jun 12;9(45):27698-27707. doi: 10.18632/oncotarget.25498. eCollection 2018 Jun 12.
  • History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.
    Kayama E, Kikuchi E, Fukumoto K, Shirotake S, Miyazaki Y, Hakozaki K, Kaneko G, Yoshimine S, Tanaka N, Takahiro M, Kanai K, Oyama M, Nakajima Y, Hara S, Monma T, Oya M.
    Clin Genitourin Cancer. 2018 Apr 28. pii: S1558-7673(18)30303-3. doi: 10.1016/j.clgc.2018.04.004. [Epub ahead of print]